JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266010

Human ATG2B knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ATG2B KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 8 and 26 bp deletion in exon 8. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human ATG2B knockout HeLa cell line (AB266010)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATG2B knockout HeLa cell line (AB266010)

Allele-2 : 10 bp deletion in exon 8.

Sanger Sequencing - Human ATG2B knockout HeLa cell line (AB266010)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATG2B knockout HeLa cell line (AB266010)

Allele-1 : 26 bp deletion in exon 8.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 8 and 26 bp deletion in exon 8

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266010-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266010 Human ATG2B knockout HeLa cell line", "number":"AB266010-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266010-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266010-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266010 Human ATG2B knockout HeLa cell line", "number":"AB266010-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266010-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266010-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266010 Human ATG2B knockout HeLa cell line", "number":"AB266010-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266010-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266010 Human ATG2B knockout HeLa cell line", "number":"AB266010-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ATG2B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ATG2B also known as Autophagy-related protein 2 homolog B plays a significant role in the autophagy process. This protein encodes a part of the essential machinery for the expansion of the autophagosome which is important for cellular degradation and recycling of cytoplasmic components. ATG2B has a molecular mass of approximately 223 kDa and shows expression in various tissues with higher levels observed in the heart and liver. Scientists study ATG2B due to its important function in maintaining cellular homeostasis.
Biological function summary

The protein facilitates the transfer of lipids necessary for the elongation of the pre-autophagosomal structure. ATG2B acts as a critical component of the ATG protein complex interacting closely with ATG9A and WIPI1 proteins. Through this complex ATG2B supports the formation and growth of autophagic membranes playing a pivotal role in cellular stress responses. The protein also affects cargo recognition during autophagy thereby influencing the selectivity of molecules degraded within the lysosome.

Pathways

The autophagy process significantly involves ATG2B within its regulatory mechanisms. This protein interacts actively in the mechanistic target of rapamycin (mTOR) signaling pathway which controls autophagy initiation and progression based on cellular nutrient status. Furthermore ATG2B shares collaborations with other related proteins within the phosphatidylinositol 3-kinase (PI3K) pathway linking it to lipid signaling mediations. These associations reinforce its role in maintaining cell survival pathways by degradation of damaged organelles and proteins.

Scientists have linked ATG2B to conditions like cancer and neurodegenerative diseases. The malfunction or alteration of ATG2B functions may result in defective autophagy contributing to the growth and survival of cancer cells by disrupting normal cellular cleanup processes. Similarly impaired ATG2B-mediated autophagy can lead to the accumulation of dysfunctional proteins a hallmark of diseases like Parkinson's. Additionally there are associations between ATG2B and proteins such as alpha-synuclein in these neurodegenerative contexts indicating a potential role in the pathology of these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com